Actavis has completed its acquisition of Allergan for a total value of around $70.5bn.
The combination of the two companies will create one of the world's top ten pharma companies by sales revenue, with combined annual pro forma revenue of more than $23bn anticipated for this year.
Brent Saunders, CEO and president of Actavis, said:
